Skip to main
ALMS

Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis Inc (ALMS) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alumis Inc. is positioned favorably in the biopharmaceutical sector through its innovative approach to developing targeted therapies for autoimmune disorders, utilizing a proprietary precision data analytics platform and leading expertise. The company's pipeline includes promising candidates such as envudeucitinib (envu), which has shown superior efficacy compared to competitors in early-stage trials, potentially establishing its dominance within the TYK2 inhibitor class. Additionally, Alumis has a strong focus on cost management, which positions it well for future financial success as the market for next-generation therapies continues to grow.

Bears say

Alumis Inc faces a negative outlook primarily due to significant risks associated with its lead pipeline candidates, specifically the inability to advance ESK-001 into pivotal trials on schedule and potential failures in demonstrating compelling efficacy in psoriasis and systemic lupus erythematosus. Additionally, the company's valuation at approximately $730 million appears disconnected from the heightened likelihood of competitive pressures and delays in regulatory approvals, which could hinder market uptake. Furthermore, ongoing concerns about possible dilution risks and overall competitive dynamics in the immunology and inflammation space further exacerbate the uncertainty surrounding Alumis's commercial prospects.

Alumis Inc (ALMS) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alumis Inc (ALMS) Forecast

Analysts have given Alumis Inc (ALMS) a Buy based on their latest research and market trends.

According to 5 analysts, Alumis Inc (ALMS) has a Buy consensus rating as of Jan 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alumis Inc (ALMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.